Exenatide vs Efpeglenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Byetta, Bydureon
Exenatide is the original GLP-1 receptor agonist and it came from an unlikely source: the saliva of the Gila monster, a venomous desert lizard. It is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human GLP-1. It was developed by Amylin and Lilly (later owned by AstraZeneca) and sold as the twice-daily Byetta (FDA-approved 2005) and the once-weekly Bydureon (2012). AstraZeneca discontinued both brands in the US in October 2024 for business reasons, not safety, and a generic twice-daily exenatide from Amneal (approved November 2024) launched in April 2025. It was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy.
Also: Eppe, HM11260C
Efpeglenatide is a long-acting, once-weekly GLP-1 agonist from Hanmi Pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. Sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. Hanmi relaunched it for obesity, and on 7 October 2026 South Korea approved it as Eppe, the country's first homegrown GLP-1 obesity drug. It is not approved by the FDA or EMA.
Key Comparison Insights
- Exenatide is FDA approved, while Efpeglenatide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to Efpeglenatide (Human Trials).
Detailed Comparison
| Attribute | Exenatide | Efpeglenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Exenatide binds and activates the GLP-1 receptor, triggering glucose-dependent insulin secretion, suppressing excess glucagon, slowing gastric emptying, and increasing satiety. The reason a lizard peptide beat human GLP-1 to market is durability: native GLP-1 is chewed up by the DPP-4 enzyme within about two minutes, while exendin-4 resists that enzyme and circulates with a half-life of roughly 2.4 hours. Endocrinologist John Eng isolated the peptide in the early 1990s after noting the Gila monster could go long stretches without eating while keeping blood sugar stable. The once-weekly Bydureon formulation traps the peptide in slowly dissolving polymer microspheres so a single injection releases drug over days. | Efpeglenatide activates the GLP-1 receptor, which raises insulin release after meals, lowers glucagon, slows stomach emptying and reduces appetite. The active part is an exendin-4 analog (the same parent peptide as exenatide and lixisenatide) attached through a small linker to a human IgG4 Fc fragment, using Hanmi's LAPSCOVERY platform. The Fc piece makes the molecule big enough to dodge kidney clearance and lets it recycle in the body, which stretches its half-life to weekly dosing. Hanmi argues its lower brain penetration explains the milder GI profile; that is a company argument rather than an independently proven fact. |
| Common Dosing | 5-10 mcg twice daily Twice daily, within 60 minutes before morning and evening meals | 10 mg once weekly maintenance (Korean label) Once weekly |
| Administration | Subcutaneous injection | Subcutaneous auto-injector once weekly |
| Typical Duration | Long-term / chronic use | Long-term (chronic weight management); 40-64 weeks in the Korean phase 3 |
| Best Time to Take | Within 60 minutes before the morning and evening meals | Same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Exenatide is a long-approved drug with a deep human trial record, not an experimental compound. Its development is well documented in the peer-reviewed literature, including a 2012 review in Regulatory Peptides tracing it from Gila monster venom to an approved antidiabetic. In type 2 diabetes trials it lowered HbA1c and produced modest weight loss, with nausea being the most common side effect, usually fading over time. The EXSCEL cardiovascular outcomes trial found once-weekly exenatide was safe for the heart but did not show a statistically significant reduction in cardiovascular events, which is part of why newer agents like semaglutide and dulaglutide have largely overtaken it. There are rare post-marketing reports of acute pancreatitis, and it is not recommended in severe kidney impairment. Overall, strong human evidence, but now considered an older option in the class. | The strongest data come from Sanofi's AMPLITUDE-O trial (NEJM 2021), which enrolled people with type 2 diabetes and cardiovascular or kidney disease. Efpeglenatide 4 or 6 mg weekly cut major cardiovascular events by 27% versus placebo (7.0% vs 9.2%, hazard ratio 0.73) over a median of 1.8 years, and also reduced kidney outcomes. Sanofi still returned the rights in 2020 for business reasons. Hanmi then ran a Korean phase 3 obesity trial in 448 adults without diabetes (average BMI 32): at 40 weeks, weight loss was 9.02% versus 0.89% on placebo, and 75.1% lost at least 5%. That is less weight loss than semaglutide or tirzepatide in their pivotal trials, though trial designs differ, and GI side effects were somewhat lower (diarrhea 17.6%, nausea 16.6%, vomiting 11.6%). Korea's MFDS approved it for chronic weight management on 7 October 2026, with launch planned for late October. Bottom line: a solid, proven drug class member with real outcome data, but modest weight loss and no Western approval. |
Frequently Asked Questions: Exenatide vs Efpeglenatide
What is the difference between Exenatide and Efpeglenatide?
Exenatide is a weight loss peptide that exenatide is the original glp-1 receptor agonist and it came from an unlikely source: the saliva of the gila monster, a venomous desert lizard. it is a synthetic 39-amino-acid peptide (a copy of the natural exendin-4) sharing about 50% of its sequence with human glp-1. it was developed by amylin and lilly (later owned by astrazeneca) and sold as the twice-daily byetta (fda-approved 2005) and the once-weekly bydureon (2012). astrazeneca discontinued both brands in the us in october 2024 for business reasons, not safety, and a generic twice-daily exenatide from amneal (approved november 2024) launched in april 2025. it was the first drug to successfully turn the short-lived incretin hormone into a real diabetes therapy. Efpeglenatide is a weight loss peptide that efpeglenatide is a long-acting, once-weekly glp-1 agonist from hanmi pharmaceutical, made by linking an exendin-4 analog to an antibody fragment so it lasts days instead of hours. sanofi licensed it for diabetes in 2015 and handed it back in 2020 despite a positive heart outcomes trial. hanmi relaunched it for obesity, and on 7 october 2026 south korea approved it as eppe, the country's first homegrown glp-1 obesity drug. it is not approved by the fda or ema. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Exenatide or Efpeglenatide?
Neither is universally "better" - the choice depends on your specific goals. Exenatide is typically used for weight loss purposes, while Efpeglenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Exenatide and Efpeglenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Exenatide and Efpeglenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.